Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)

Trial Profile

Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ALTER0703
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 15 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 14 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top